10 February 2026
10 February 2026
Drug developers integrate AI capabilities as a potentially transformative strategy to combat patent cliff losses.
Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings.
Lilly joins the growing list of big pharma companies hoping to see success from their acquired in vivo CAR-T programmes.
The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.
REGENXBIO plans to request a Type A meeting with the FDA to discuss the CRL and its planned BLA resubmission.
Despite the FDA’s CNPV scheme generating high interest, the process around how voucher awards are prioritised remains unclear.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
